Big Insulin Makers Spent Big Money on Lobbying in 2021

Two of the top producers of insulin increased their lobbying efforts last year amid public cries for pricing reform for all drugs, but insulin in particular.

According to lobbying disclosures, Eli Lilly shelled out $7 million on lobbying in 2021, which represents an almost 30 percent increase over 2020, but was similar to what the company spent in 2019.

Another big maker of insulin, Novo Nordisk, spent $3.2 million, almost a quarter more than in 2020.

Sanofi, the third big player in the insulin market, kept its lobbying expenditures relatively flat from 2020 to 2021 at approximately $3.7 million.